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Abstract
Background and Aims: To evaluate the clinical outcomes in patients with IBD after switching from 
Remicade® to CT-P13 in comparison with patients who maintain Remicade®.
Methods: Patients under Remicade® who were in clinical remission with standard dosage at 
study entry were included. The ‘switch cohort’ [SC] comprised patients who made the switch from 
Remicade® to CT-P13, and the ‘non-switch’ cohort [NC] patients remained under Remicade®.
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Results: A total of 476 patients were included: 199 [42%] in the SC and 277 [58%] in the NC. The 
median follow-up was 18 months in the SC and 23 months in the NC [p < 0.01]. Twenty-four out of 
277 patients relapsed in the NC; the incidence of relapse was 5% per patient-year. The cumulative 
incidence of relapse was 2% at 6 months and 10% at 24 months in this group. Thirty-eight out of 199 
patients relapsed in the SC; the incidence rate of relapse was 14% per patient-year. The cumulative 
incidence of relapse was 5% at 6 months and 28% at 24 months. In the multivariate analysis, the 
switch to CT-P13 was associated with a higher risk of relapse (HR = 3.5, 95% confidence interval 
[CI] = 2–6). Thirteen percent of patients had adverse events in the NC, compared with 6% in the SC 
[p < 0.05].
Conclusions: Switching from Remicade® to CT-P13 might be associated with a higher risk of clinical 
relapse, although this fact was not supported in our study by an increase in objective markers of 
inflammation. The nocebo effect might have influenced this result. Switching from Remicade® to 
CT-P13 was safe.
Key Words: Inflammatory bowel disease; Crohn’s disease; ulcerative colitis; switch; Remicade®; sup > CT-P13
1. Introduction
Inflammatory bowel disease [IBD] is a chronic disorder of complex 
etiology, only partially understood, that involves a pathological re-
sponse of both the innate and acquired immune system, resulting 
in chronic inflammation of the gastrointestinal tract. Inflammatory 
bowel disease is the result of the interaction of different factors, 
including genetic susceptibility, environmental factors, infectious 
agents, commensal enteric flora, and immunological alterations.
The era of biologic therapy in the treatment of IBD began in 
1998 when the Food and Drug Administration approved infliximab, 
the first drug directed against tumor necrosis factor-alpha, for the 
treatment of patients with Crohn’s disease [CD]. Anti-TNF drugs 
have represented a milestone in the treatment of patients with IBD 
in recent years, decreasing the need for surgery and hospital admis-
sions, and more importantly improving the quality of life. They also 
have a good safety profile.1
Recently, due to the expiration of the original infliximab patent 
[Remicade®], several biosimilar drugs have been developed with 
the fundamental objectives of reducing health-care expenditure on 
costly biologic treatments and improving the access of patients to 
these drugs. In 2013, the European Medicines Agency approved 
the infliximab biosimilars Inflectra® and Remsima®, both CT-P13. 
In the approval process, similarity was demonstrated in preclinical 
tests, followed by clinical studies in patients with rheumatoid arth-
ritis [PLANETRA] and ankylosing spondylitis [PLANETAS], which 
showed that CT-P13 was comparable with Remicade® in terms of 
efficacy, safety, pharmacokinetics, and immunogenicity.2, 3 Based on 
these results, the approval was extended to include all the indications 
approved for the originator, including IBD. After much controversy 
about the efficacy of CT-P13 in IBD, the major drivers for its use are 
cost saving for the health system and patient access; thus, the use of 
CT-P13 in patients starting infliximab treatment has become widely 
accepted.
Despite the initial reluctance, the use of biosimilars is growing; 
therefore, it is mandatory to fully understand the outcomes in pa-
tients treated with biosimilar agents, not only in naïve patients, but 
also after switching from the originator. However, data about the 
effectiveness and safety of the switch from Remicade® to CT-P13, 
particularly in IBD patients, is limited. In this respect, only one ran-
domized clinical trial has evaluated the outcomes after switching 
from Remicade® to CT-P13 [NOR-SWITCH trial]; this study has 
several methodological limitations, so its results must be interpreted 
with caution, especially for IBD.4
In clinical practice, few studies have evaluated the switch from 
Remicade® to CT-P13 in IBD patients, all of them with several limi-
tations: most of them were retrospective, with few patients included, 
short-term follow-up, and lack of a control group.5–11 Therefore, 
the aim of our study was to evaluate in IBD patients the outcomes, 
both in the short- and long-term, after switching from Remicade® 
to CT-P13, compared with patients who remain on the original 
drug. This study will provide post-marketing information useful for 
understanding IBD patients’ outcomes after switching, which will 
help decision-making in clinical practice, and better management of 
the arrival in the near future of new biosimilars to the therapeutic 
armamentarium for IBD.
2. Methods
2.1. Study design
This was a retrospective, cohort, multicentre study in which pa-
tients with IBD in stable treatment with infliximab at standard doses 
were included. The switch cohort [SC] comprised the patients who 
switched treatment, while the non-switch cohort [NC] comprised 
the patients who remained on the original drug. The main outcome 
was the proportion of patients with clinical relapse throughout the 
follow-up. Demographic data, characteristics of IBD, pharmaco-
logical treatments, and surgeries due to IBD were collected from 
the diagnosis records. Whenever available, results from radiological 
and endoscopic examination at the end of follow-up were included. 
The protocol was approved by Ethics Committee of the Clinical 
Research of Hospital Universitario de La Princesa.
2.2. Study population
The study included patients older than 18  years diagnosed with 
IBD, in clinical remission at the time of the start of follow-up—
defined as a Partial Mayo Score [PMS] of ≤2 in ulcerative colitis 
[UC],12 and a score of ≤4 in the Harvey–Bradshaw index [HBI] 
in CD13—and treated with infliximab as the first biologic agent, 
in the first attempt of treatment with this drug and receiving the 
drug at standard dosage. The study excluded patients treated with 
infliximab for an indication other than IBD, those who started 
the treatment with infliximab while being in remission [e.g. as 
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prophylaxis of postoperative recurrence] and those who had re-
ceived treatment with infliximab with a dosage lower or higher 
than the standard.
Patients of the SC came from centres that made the switch as 
a generalized practice for all of their patients, to avoid the selec-
tion bias that might be caused by choosing to make the switch in 
those patients who theoretically were more stable and had less 
risk of relapse. After the approval of the biosimilar infliximab by 
the Spanish Agency of Medicines and Health Products, CT-P13 
was the only infliximab available in the Pharmacy of those hos-
pitals. In addition, patients were informed about the switch but 
they were not asked about their preferences. Patients from the NC 
came from centres that did not switch from Remicade® to CT-P13 
for any patient.
2.3. Data collection
Study data were collected and managed using an electronic data 
capture tool [Research Electronic Data Capture14], which is hosted 
at Asociación Española de Gastroenterología [AEG; www.aegastro.
es],14 a non-profit scientific and medical society focusing on gastro-
enterology. AEG provided this service free of charge, with the 
sole aim of promoting independent investigator-driven research. 
REDCap is a secure, web-based application designed to support data 
capture for research studies that provides the following: [i] an intui-
tive interface for validated data entry; [ii] audit trails for tracking 
data manipulation and export procedures; [iii] automated export 
procedures for seamless data downloads to common statistical pack-
ages; and [iv] procedures for importing data from external sources. 
This system allows remote monitoring, which was carried out by the 
leading group.
2.4. Study follow-up
In the case of the SC, the follow-up started for each patient on 
the date of switching and ended on the date of relapse, the date of 
CT-P13 interruption, or the date of the last visit [whichever occurred 
first]. In the NC, the follow-up started in March 2015 [the date when 
the switch was initiated as a generalized practice in the centres that 
carried out the switch strategy] and ended the date of Remicade® 
interruption, the date of relapse, or the date of the last visit [which-
ever occurred first]. All patients who met the inclusion criteria in 
each participating centre were included in this study to avoid selec-
tion bias.
2.5. Definitions
2.5.1. Clinical activity
Clinical relapse was defined as an HBI of >4 points in patients 
with CD. In UC, clinical recurrence was defined as a PMS of >2 
points.
Endoscopic/radiologic activity: Information about endoscopic or 
radiologic activity was provided only in cases in which those explor-
ations were performed. In CD, endoscopic activity was rated based 
on the endoscopist’s criteria [mild, moderate, or severe activity]. 
Rutgeerts score was used to rate endoscopic activity in CD patients 
in postoperative setting. In UC, endoscopic severity was rated based 
on the endoscopic subscore of the Mayo index. Only complete col-
onoscopies with ileoscopy were considered in CD patients with ileal 
involvement. Radiologic activity assessment was based on radiolo-
gists’ criteria focused on the increase in bowel wall thickness and 
enhancement with intravenous gadolinium, with or without accom-
panying perienteric changes.
2.6. Statistical analysis
For categorical variables, percentages were calculated (with their 
95% confidence intervals [CIs]). The descriptive analysis of quan-
titative variables calculated the mean and standard deviation [SD], 
or the median and interquartile range [IQR], depending on whether 
they were normally distributed or not. In the univariate analysis, 
categorical variables were compared using the Chi-square [χ2] test, 
and quantitative variables using the appropriate test. Bonferroni cor-
rection was applied in case of multiple comparisons; for example, 
when comparing C-reactive protein [CRP] concentration between 
cohorts and in patients with and without relapse within each cohort; 
statistical significance was considered present when p was <0.008 
[six comparisons].
The Kaplan–Meier method, when patients who relapsed were 
censored, was used to evaluate the cumulative incidence of relapse, 
and any differences between survival curves were evaluated with the 
log-rank test. Stepwise multivariate analysis using the Cox model 
was used to investigate factors potentially associated with patient re-
lapse. In the log-rank test and in the multivariate analysis, statistical 
significance was considered present when p was <0.05.
3. Results
A total of 476 patients were included: 42% in the SC and 58% 
in the NC. The median follow-up was 18  months (Interquartile 
range [IQR]  =  10–22  months) in the SC and 23  months 
[IQR  =  19–25  months] in the NC [p  <  0.01]. The median time 
of treatment with Remicade® before starting the follow-up was 
similar in both cohorts [45 months in the SC and 37 in the NC]. 
The characteristics of both cohorts are summarized in Table 1. 
Female gender and the proportion of patients with perianal CD 
were significantly higher in the SC, while the proportion of patients 
with previous surgery due to IBD was higher in the NC. With re-
spect to the indication of infliximab treatment, the proportion of 
patients that received infliximab due to top-down strategy was sig-
nificantly higher in the NC, whereas the proportion of patients that 
received infliximab due to steroid dependency was significantly 
higher in the SC. The distribution of other characteristics did not 
differ between both cohorts.
3.1. Effectiveness
Of the 199 patients in the SC, 38 relapsed after a median follow-up of 
18 months [IQR = 10–22 months]. In the NC, 24 out of 277 patients 
relapsed after a median follow-up of 23 months [IQR = 19–25]. The 
incidence rate of relapse was significantly higher in patients in the 
SC [14% per patient-year, 95% CI = 10–18.9%] than in patients 
in the NC [5% per patient-year, 95% CI = 2.9–7.1%] [p < 0.05]. 
The cumulative incidence of relapse was 5% at 6 months, 14% at 
12 months, and 28% at 24 months in the SC, and 2% at 6 months, 
4% at 12  months, and 10% at 24  months in the NC [p  <  0.05] 
[Figure 1].
In the univariate analysis, infliximab treatment due to steroid 
dependency and switch from Remicade® to CT-P13 [vs maintained 
on Remicade® treatment] were significantly associated with higher 
risk of relapse. In the multivariate analysis, switch from Remicade® 
to CT-P13 [vs maintained on Remicade® treatment], adjusted by 
the time on infliximab treatment before starting the follow-up, 
was the only factor significantly associated with higher risk of re-
lapse [hazard ratio  =  3.5, 95% CI  =  2–6]. Other factors such as 
type of IBD, concomitant treatment with immunosuppressant, 
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Figure 1. Cumulative incidence of relapse in patients maintained on Remicade® and in patients switched to CT-PT13.
Table 1. Characteristics of the study population.
Switch cohort [N = 199] Non-switch cohort [N = 277] p
Age [years] [median, IQR] 42 [31–53] 43 [31–52] N.S.
Time of IBD evolution before starting 
infliximab [months] [median, IQR]
45 [13–187] 48 [12–139] N.S
Time under infliximab treatment at the begin-
ning of follow-up [months] [median, IQR]
45 [17–81] 37 [17–58] N.S.
Time of follow-up [months] [median, IQR] 18 [10–22] 23 [19–25] <0.01
Female gender, n [%] 107 [54] 111 [40] <0.01
Crohn’s disease, n [%] 142 [71] 211 [76] N.S.
 Ileal, n [%] 44 [31] 84 [40] N.S.
 Colonic, n [%] 44 [31] 42 [20]
 Ileocolonic, n [%] 54 [38] 85 [40]
 Upper GI tract, n [%] 11 [5.5] 15 [5.4]
 Inflammatory phenotype, n [%] 84 [59] 115 [54] N.S.
 Stricturing phenotype, n [%] 22 [16] 31 [15]
 Fistulizing phenotype, n [%] 36 [25] 65 [31]
Perianal, n [%] 76 [38] 81 [29] <0.05
Ulcerative colitis, n [%] 57 [29] 66 [24] N.S.
 Pancolitis, n [%] 32 [56] 38 [58] N.S.
 Left-sided colitis, n [%] 19 [33] 25 [38]
Extraintestinal manifestations, n [%] 51 [25.6] 64 [23] N.S.
 Surgery, n [%] 51 [25.6] 96 [34.7] <0.05
Indication for infliximab treatment    
 Refractoriness to immunomodulators, n [%] 101 [51] 130 [47] N.S.
 Intolerance to immunomodulators, n [%] 30 [15] 32 [11.6] N.S.
 Top-down strategy, n [%] 2 [1] 17 [6] <0.01
 Steroid-dependency, n [%] 57 [28.6] 44 [16] <0.01
 Steroid-refractoriness, n [%] 18 [9] 27 [10] N.S.
 Fistulizing disease, n [%] 33 [16.6] 45 [16] N.S.
 Perianal disease, n [%] 31 [15.6] 33 [12] N.S.
Concommitant treatments    
 Mesalazine, n [%] 46 [23] 55 [20] N.S.
 Azathioprine, n [%] 90 [45] 112 [40.4] N.S.
 Mercaptopurine, n [%] 3 [1.5] 7 [2.5] N.S.
 Methotrexate, n [%] 13 [6.5] 12 [4.3] N.S.
Non-statistically significant, N.S.; interquartile range, IQR.
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extraintestinal manifestations, and previous surgery were not associ-
ated with risk of relapse [Table 2].
Median CRP concentration was similar at baseline and at the 
end of follow-up both in the SC and the NC [0.14 mg/dL vs 0.2 mg/
dL, p > 0.05, and 0.19 mg/dL vs 0.2 mg/dL, p > 0.05, respectively]. 
The median CRP concentration was also similar at baseline and 
at the end of follow-up within the SC [0.14 mg/dL vs 0.19 mg/dL, 
p > 0.05] and within the NC [0.2 mg/dL vs 0.2 mg/dL, p > 0.05]. 
Moreover, this parameter did not change between baseline and the 
end of follow-up in patients who maintained remission within the 
SC [0.2 mg/dL vs 0.19 mg/dL, p > 0.05].] or within the NC [0.2 mg/
dL vs 0.17  mg/dL, p  >  0.05]. However, the median CRP concen-
tration was significantly higher at the end of follow-up than it was 
at baseline in patients who relapsed, both in the SC [0.6 mg/dL vs 
0.12 mg/dL, p < 0.001] and in the NC [0.8 mg/dL vs 0.2 mg/dL, 
p < 0.001].
A total of 152 patients [32%] had endoscopic/radiologic assess-
ment at the end of follow-up. In the SC, 67 [33%] had endoscopic/
radiologic assessment: 9 of them had clinical relapse, and 7 of these 9 
patients had active inflammation in the endoscopic/radiologic exam-
ination. In the NC, 85 patients [30%] had endoscopic/radiologic 
assessment: 11 of them had clinical relapse; endoscopic/radiologic 
activity was present in 7 out of these 11 patients with clinical relapse.
3.2. Safety
A total of 48 patients developed 61 adverse events during follow-up. 
The proportion of patients that developed adverse events was 13% 
in the NS and 6% in the SC [p < 0.05]. Main adverse events are sum-
marized in Table 3.
3.3. Reasons for treatment cessation
From 277 patients in the non-switch cohort, 24 [8.7%] relapsed and 
209 [75.5] were receiving Remicade® at the last visit. In addition, 24 
patients [8.7%] stopped the treatment with Remicade® before the 
last visit, 18 [6.5%] changed the biologic treatment for a reason dif-
ferent from IBD, and 2 [0.7%] were switched to CT-P13.
On the other hand, from 199 patients in the SC, 38 patients 
[19%] relapsed after switching to CT-P13, and 115 [57.8%] main-
tained the treatment with CT-P13 at the last visit. In addition, 43 
[21.6%] stopped the treatment with CT-P13 before last visit, and 3 
[1.5%] had to change the biologic treatment for a reason different 
from IBD.
4. Discussion
To the best of our knowledge, this is the largest study with the longest 
follow-up that has evaluated the outcomes of IBD patients in remis-
sion switched from Remicade® to CT-P13 in clinical practice, com-
paring them with a control group of patients who were maintained 
on Remicade®. We observed that the cumulative incidence of clinical 
relapse was significantly higher in patients switched to CT-P13 than 
in those who maintained Remicade® [14% per patient-year vs 5% 
per patient-year, respectively].
As a secondary end point, we analysed the changes in the CRP 
concentration, as an objective marker of disease activity. The me-
dian CRP concentration at baseline was similar in the SC and the 
NC, and, overall, it did not change between baseline and the end 
of follow-up in any of these groups. Therefore, differences in clin-
ical relapse were not supported by differences in biomarkers of 
inflammation.
Up till now, few studies have evaluated the evolution of IBD pa-
tients switched from Remicade® to CT-P13. In a recent review pub-
lished by our group, disease control [absence of disease worsening 
after switching] was confirmed in 88% of patients after the switch.15 
Another systematic review evaluated the efficacy of biosimilars after 
switching from Remicade® to CT-P13, finding that pooled rates of 
sustained clinical remission among CD and UC patients at 16 and 
51 weeks after switching were 74% and 92% in CD, and 62% and 
83% in UC.16 All these figures are similar to the cumulative inci-
dences of relapse reported in our study, in which 14% of patients 
per year relapsed after switching. In addition, this incidence rate is 
similar to that observed in IBD patients under Remicade® [~13% per 
patient-year].17, 18
The NOR-SWITCH trial is the only randomized controlled trial 
that has examined non-medical switching of CT-P13 across indica-
tions.4 Across all diagnoses, the proportion of patients with disease 
worsening after 52 weeks was 26.2% for the Remicade® arm and 
29.6% for the CT-P13 arm. In UC, disease worsening was reported 
in 9.1% of patients with Remicade® and in 11.9% with CT-P13. 
However, there was a trend towards higher risk of disease worsening 
in CD patients switched to CT-P13: 21.2% of patients treated with 
Remicade® and 36.5% of patients treated with CT-P13 [difference 
–14.3%, with a non-inferiority margin set to 15%]. Although au-
thors concluded that it is effective and safe to switch biologic 
therapy, the NOR-SWITCH trial has some limitations that might 
impact the interpretation of the results.
Although our results suggest that switching from Remicade® to 
CT-P13 in IBD patients might have a negative impact on patients’ 
clinical outcomes, the difference between the cohorts [SC and NC] is 
not necessarily attributable to CT-P13 itself, but could also represent 
a ‘nocebo effect’. The nocebo effect is also called the ‘evil brother of 
the placebo effect’ and has become a subject of growing interest.21 
Nocebo response usually refers to new and worsening symptoms 
that are caused only by negative expectations of the patient or nega-
tive verbal and non-verbal communications from the treating person. 
Thus, nocebo effects can modulate the outcome of a given therapy in 
a negative way, much as placebo effects do in a positive way.
Boone et  al. have described infliximab biosimilar implementa-
tion in IBD and rheumatology practice, particularly focusing on the 
nocebo response by quantifying patients’ acceptance.22 In this study, 
an overall nocebo response of 13% was found among the patients 
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Table 2 Multivariate analysis of factors associated with the risk of 
relapse during follow-up.
Hazard  
ratio
95% confidence 
interval
Switch cohort [vs non-switch cohort] 3.5 2–6
Time under infliximab treatment at  
the beginning of follow-up [months]
0.99 0.98–1.01
Table 3. Adverse events during follow-up.
Switch 
cohort
Non-switch 
cohort
p
Infections, n [%] 1 [0.5] 18 [6.5] <0.05
Infusional reac-
tions, n [%]
0 6 [2.2] <0.05
Lupus, n [%] 0 2 [0.7] >0.05
Skin lesions, n [%] 3 [1.5] 11 [4] >0.05
Others, n [%] 8 [0.4] 2 [0.7] <0.05
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during a minimal observation period of 6 months after the switch to 
CT-P13, which is higher than the difference in the incidence rate of 
relapse that we found between the SC and the NC [11%]. Authors 
observed that patient empowerment and registration of treatment 
outcomes could reduce nocebo response rates.
Two recent surveys investigating patients’ and physicians’ per-
spectives on biosimilar drugs showed that the majority of responders 
had concerns about the safety and efficacy of biosimilar agents.23, 24 
Given the uncertainties regarding the efficacy and safety of CT-P13 
in IBD patients, and the beliefs of both clinicians and patients, the 
introduction of CT-P13 must be done in a carefully controlled en-
vironment. In this respect, Razanskaite et al. published the outcomes 
of a service evaluation of switching IBD patients under Remicade® 
to CT-P13, using a managed switching program funded via a gain 
share agreement in the UK.7 The early results of the program did not 
reveal significant differences in patients’ outcomes after switching. 
The authors highlighted that, by ensuring the incentivization of all 
the stakeholders, including patients, the agreement is important for 
the success of a switching program.
With respect to the safety of the switch, in our study the pro-
portion of patients with adverse events was significantly higher in 
the NC than in the SC. The proportion of patients with adverse 
events was within the expected limits in both groups. However, 
due to the retrospective design of the study, the registration of 
adverse events largely depends on the awareness of the clinician, 
and therefore mild adverse events might be underreported. Based 
on our results, we can conclude that switching from the origin-
ator to CT-P13 is a safe strategy; the higher proportion of patients 
with adverse events in the NC might be irrelevant from the clinical 
point of view.
Limitations of our study include the fact that the switch was 
unblinded. The double-blind set-up of the NOR-SWITCH trial ex-
cludes possible bias caused by the nocebo effect; however, blinded 
transition to a biosimilar drug is not allowed in daily practice. In 
fact, the effects of open-label transitioning to CT-P13 are of great 
interest because they reflect what happens in real life. In this respect, 
although patients of the SC came from centres that made the switch 
as a generalized practice for all their patients, and patients from 
the NC came from centres that did not switch from Remicade® to 
CT-P13 in any patient, differences in practices in different centres 
could not be ruled out as a potential cause of bias.
In addition, the main outcome of our study was clinical relapse, 
which was based on HBI and PMS. These scores include subjective 
symptoms, which can be easily modulated by patients’ and clin-
icians’ beliefs and expectations. However, CRP concentration, which 
is an objective marker of inflammation, showed no differences be-
tween the SC and NC; therefore, differences in clinical relapse rate 
were not associated with differences in objective biomarkers of in-
flammation, suggesting that the nocebo effect phenomena might be 
causing the onset of clinical symptoms within the SC.
One-third of the patients had endoscopic/radiologic assessment 
at the end of follow-up. Most of the patients with endoscopic/
radiologic evaluation and clinical relapse had active inflammation; 
however, a selection bias towards performing complementary exam-
inations in the most severe patients cannot be ruled out. In add-
ition, due to the characteristics of the Mayo endoscopic score, it 
is possible to calculate it retrospectively, with the information that 
is commonly included in the endoscopic report; in fact, the Mayo 
endoscopic score is routinely used in many endoscopic units to rate 
the activity in UC patients. On the contrary, it is not possible to cal-
culate the SES-CD score retrospectively based on the description of 
the findings in the endoscopic report. Finally, data of trough levels 
of Remicade® or CT-P13 and antibodies against infliximab were not 
available in our study, and therefore we could not assess whether dif-
ferences in the pharmacokinetics of the drugs existed. Nevertheless, 
no infusional reactions were reported in the SC [vs 6 in the NC], and 
previous studies have proven that there is no increased risk of im-
munogenicity in patients switched to CT-P13.4, 10, 25
Our study is the largest so far including patients switched from 
Remicade® to CT-P13 in clinical practice. More importantly, we 
were able to directly compare the outcomes for patients switched 
to CT-P13 with those of patients maintained on Remicade®. As this 
is an observational study, to avoid selection bias, only centres where 
the switch was performed for all their patients were included. Finally, 
our cohorts were very homogeneous. In this regard, infliximab was 
the first line of biologic treatment in those patients, all of them were 
in clinical remission with infliximab at the standard dose, and none 
of them had received an escalated dose.
In conclusion, switching from Remicade® to CT-P13 might be 
associated with a higher risk of clinical relapse in IBD patients [in 
comparison with those maintained on Remicade®], although this 
fact was not supported in our study by an increase in objective 
markers of inflammation. However, due to the study design, a no-
cebo effect cannot be ruled out as a factor influencing this difference. 
The introduction of biosimilar agents as a treatment option for IBD 
patients could achieve substantial cost saving for health-care sys-
tems. However, given the significant impact that nocebo effects can 
have on patients’ quality of life and health services, it is important 
to develop interventions to minimize the appearance of these effects. 
With new biosimilar agents entering the market in the near future, 
specific programs based on gain share agreements should be devel-
oped to ensure that all stakeholders are convinced and motivated to 
accept the switch, with the consequent benefits to the patients and 
the health-care system.
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